a Neurogenetics Section, Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science , Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health , Toronto , ON , Canada.
b Department of Psychiatry , University of Toronto , Toronto , ON , Canada.
World J Biol Psychiatry. 2019 Jan;20(1):91-95. doi: 10.1080/15622975.2017.1301681. Epub 2017 Apr 10.
Tardive dyskinesia (TD) is a movement disorder that may develop as a side effect of antipsychotic medication. The aetiology underlying TD is unclear, but a number of mechanisms have been proposed.
We investigated single-nucleotide polymorphisms (SNPs) in the genes coding for neuregulin-1 and erbB-4 receptor in our sample of 153 European schizophrenia patients for possible association with TD.
We found the ERBB4 rs839523 CC genotype to be associated with risk for TD occurrence and increased severity as measured by the Abnormal Involuntary Movement Scale (AIMS) (P = .003).
This study supports a role for the neuregulin signalling pathway in TD, although independent replications are warranted.
迟发性运动障碍（TD）是一种运动障碍，可能是抗精神病药物的副作用。TD 的病因尚不清楚，但提出了许多机制。
我们研究了编码神经调节蛋白 1 和 erbB-4 受体的基因中的单核苷酸多态性（SNPs），以探讨其与我们的 153 例欧洲精神分裂症患者 TD 发生的可能关联。
我们发现 ERBB4 rs839523 CC 基因型与 TD 发生的风险以及用异常不自主运动量表（AIMS）测量的严重程度增加相关（P = .003）。
这项研究支持神经调节素信号通路在 TD 中的作用，尽管需要独立的复制。
